TYRA
HEALTHCARETyra Biosciences Inc
$33.80-0.13 (-0.38%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TYRA Today?
No stock-specific AI insight has been generated for TYRA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.75$40.65
$33.80
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-2.01
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume526K
Avg Volume (10D)—
Shares Outstanding59.5M
TYRA News
20 articles- Tyra Biosciences to Participate in Upcoming Investor ConferencesYahoo Finance·May 7, 2026
- Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug DabogratinibYahoo Finance·Apr 24, 2026
- Tyra Biosciences Announces Appointment of Habib Dable to its Board of DirectorsYahoo Finance·Apr 17, 2026
- A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial ProgressYahoo Finance·Apr 4, 2026
- This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New PositionMotley Fool·Mar 20, 2026
- Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.Motley Fool·Mar 19, 2026
- Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million ExitMotley Fool·Mar 18, 2026
- Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million ExitMotley Fool·Mar 18, 2026
- Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative?Yahoo Finance·Mar 4, 2026
- Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent HighlightsYahoo Finance·Mar 2, 2026
- Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia DataMarketbeat·Mar 2, 2026
- Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers SymposiumYahoo Finance·Feb 23, 2026
- From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million BackerMotley Fool·Feb 23, 2026
- Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million StakeMotley Fool·Feb 23, 2026
- Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 MillionMotley Fool·Feb 23, 2026
- Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%Motley Fool·Feb 23, 2026
- Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%Motley Fool·Feb 23, 2026
- Tyra Biosciences price target raised to $53 from $37 at WedbushYahoo Finance·Feb 14, 2026
- Does Tyra Biosciences (TYRA) Index Inclusion Mark a Turning Point in Its Institutional Story?Yahoo Finance·Dec 25, 2025
- Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% RallyMotley Fool·Dec 23, 2025
All 20 articles loaded
Price Data
Open$35.00
Previous Close$33.93
Day High$35.54
Day Low$33.03
52 Week High$40.65
52 Week Low$8.75
52-Week Range
$8.75$40.65
$33.80
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-2.01
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume526K
Avg Volume (10D)—
Shares Outstanding59.5M
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes for cancer patients. The company is headquartered in Carlsbad, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—